#zepbound #tirzepatide #wegovy #semaglutide #weight loss #obesity #health #pharmaceuticals
Learn about the trial results of Zepbound, a new weight loss medication that has shown significant success in helping patients lose weight.
#health #obesity #glp1 #who #guidelines
WHO endorses GLP-1 therapies for obesity, emphasizing long-term use with lifestyle interventions.
#healthcare #pharma #pricing #obesity
Eli Lilly trims Zepbound vial prices to $499/month for self-pay patients, signaling broader obesity drug affordability amid industry and political pushes.
#heart_attacks #medical_technology #obesity
Learn about the recent study showing a significant decrease in heart attack deaths in American adults over the past five decades.
#pfizer #metsera #obesity #biotech #pharma
Pfizer secures a $10B deal to acquire Metsera, boosting obesity therapies and signaling strategic growth in biotech.
#eli_lilly #obesity #pharmaceutical #healthcare
Learn about Eli Lilly's successful Phase 3 trial for orforglipron as a treatment for obesity and its potential impact on the pharmaceutical company and healthcare industry.
